The Food and Drug Administration (FDA), in partnership with the Local Government Units (LGUs), launches the Bigyang-halaga, Bangon MSMEs (Micro, Small, and Medium Enterprises) Program.
To address the socioeconomic impacts of the pandemic, there is a need, indeed, to improve the investment climate to open up opportunities for job creation, particularly in manufacturing and the formal services sector. The collective mindset in this recovery time is to aspire for growth that is more inclusive so that all Filipinos, including the poor, are given opportunities to participate in the growing economy. Critical to that is the success in generating high-quality jobs and raising productivity.
Food and Drug Administration (FDA) Director General Dr. Samuel A. Zacate launches the Bigyang-halaga, Bangon MSMEs (BBM MSME) program, which aims to assist and capacitate local entrepreneurs, particularly the Micro, Small, and Medium Enterprises (MSMEs), recognizing that the challenge for MSMEs is on insufficiency, if not lack of knowledge on the technical and safety requirements (i.e. good manufacturing practices) of law specific to their activities in the supply chain and the procedures adopted by the FDA either due to limited technical and/or financial capacity.
In accordance with the principles laid down under Republic Act (RA) No. 9501, otherwise known as “An Act to Promote Entrepreneurship by Strengthening Development and Assistance Programs to Micro, Small and Medium Scale Enterprises, amending for the Purpose RA No. 6977, as amended, otherwise known as the ‘Magna Carta for Small Scale Enterprises’ and for Other Purposes”, the FDA recognizes the need to promote, support, strengthen, and encourage the growth and development of MSMEs in partnership with the Local Government Units (LGUs) to help MSME’s within their respective jurisdictions.
Hence, as part of the FDA’s assistance to MSMEs, recognizing their specific needs, promoting entrepreneurship, supporting entrepreneurs, encouraging the establishment of MSMEs and ensuring their continuing viability and growth, and at the same time sustaining the FDA’s mission, quality policy, and objectives of (i) ensuring the FDA’s monitoring and regulatory coverage over establishments and products under its jurisdiction; (ii) enhancing industry and consumer confidence in the regulatory system; and (iii) helping achieve economic growth and development by promoting fair trade practices and sound regulatory foundation for domestic and international trade, a committee is hereby established.